X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Efficacy Shown On Cystic Fibrosis Patients In 4-Year Study

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Efficacy Shown On Cystic Fibrosis Patients In 4-Year Study

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development

Silence and Hansoh partner to develop siRNA-based treatments

Content Team by Content Team
26th October 2021
in Drug Development, News
Siemens and BioNTech expand their collaboration for global vaccine production

Silence Therapeutics and Hansoh Pharmaceutical have entered a partnership to develop small-interfering ribonucleic acid (siRNAs) drugs for three undisclosed targets using the former’s mRNAi GOLD platform.

Following the conclusion of the Phase I clinical trial, Hansoh will hold an exclusive option to licence rights to the first two targets in Hong Kong, Macau, Greater China and Taiwan.

For all the other territories, Silence will maintain exclusive rights for the two targets.

Furthermore, Silence will oversee all works until option exercise and will be responsible for developing the targets outside of China after Phase I trials.

Hansoh will hold an exclusive option to licence the international global rights to a third target during the filing of an investigational new drug (IND) application.

The company will also handle all the development works on the third target after the option exercise.

Hansoh Pharma executive director Eliza Sun said: “We see substantial opportunity in Silence’s mRNAi GOLD platform to develop and bring better precision-based medicines to patients across China and worldwide.”

As per the agreement, Silence is eligible to get an upfront payment of $16m from Hansoh, which will also make additional payments of up to $1.3bn on meeting development, regulatory and commercial milestones.

Hansoh will also make tiered royalty payments to Silence on net sales of the products.

Silence Therapeutics president and CEO Mark Rothera said: “This collaboration is a good example of our hybrid model in action, balancing proprietary and partnered programmes to maximise the substantial opportunity of our mRNAi GOLD platform for targeting disease-associated genes in the liver.

“The Hansoh partnership enables us to move two new proprietary programmes forward subsidised by non-dilutive capital while also gaining access to the second largest pharmaceutical market globally.”

In March last year, Silence Therapeutics partnered with AstraZeneca for the discovery, development and commercialisation of small interfering RNA (siRNA) drugs for cardiovascular, renal, metabolic and respiratory diseases.

Previous Post

UCB to license its AI technology that improves identification of Osteoporosis to ImageBiopsy Lab

Next Post

GTP Bioways invests €12M in two GMP biopharmaceutical production units

Related Posts

Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Drug Development

AADC Inadequacy To Be Handled By A Novel Gene Therapy

24th March 2023
Drug Development

New Drug Explored For Epilepsy Gets $3M Funding In Australia

23rd March 2023
Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials
Clinical Trials

Faster Clinical Trial Nods Planned By The UK To Curb Issues

22nd March 2023
Pharma Drugs Gain From Tardigrade Proteins, Says Research
Drug Development

Pharma Drugs Gain From Tardigrade Proteins, Says Research

22nd March 2023
Next Post
GTP Bioways invests €12M in two GMP biopharmaceutical production units

GTP Bioways invests €12M in two GMP biopharmaceutical production units

Latest News

Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Drug Development

AADC Inadequacy To Be Handled By A Novel Gene Therapy

24th March 2023
Drug Development

New Drug Explored For Epilepsy Gets $3M Funding In Australia

23rd March 2023
Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials
Clinical Trials

Faster Clinical Trial Nods Planned By The UK To Curb Issues

22nd March 2023
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In